Results 1 to 10 of about 3,562 (130)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

Diagnostics, 2020
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival.
Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis   +10 more
doaj   +3 more sources

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report [PDF]

Frontiers in Oncology
Meningiomas are the most common primary intracranial tumor in adults. Beyond surgery and radiation, no standard of care therapy exists. Meningiomas overexpress somatostatin receptor 2 (SSTR2), providing the rationale for somatostatin analogue-based ...
Carlen A. Yuen, Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, David O. Kamson, Eleanor Chu, Eleanor Chu, Jennifer E. Soun, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Frank P. Hsu, Hansen Bow, Hansen Bow, Michelle Zheng, Shyam M. Srinivas   +15 more
doaj   +2 more sources

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. [PDF]

Cancers (Basel), 2023
Merola E, Grana CM.
europepmc   +2 more sources

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. [PDF]

J Clin Med, 2021
Camus B, Cottereau AS, Palmieri LJ, Dermine S, Tenenbaum F, Brezault C, Coriat R.   +6 more
europepmc   +2 more sources

Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database. [PDF]

J Neuroendocrinol
Abstract Introduction: VIPoma is an extremely rare functioning pancreatic neuroendocrine tumor. Therefore, data regarding treatment and outcome are very limited. Aim (s): This multicenter study aimed to analyze clinical characteristics, real‐world management, and outcomes of patients with VIPoma.
Bartsch DK, Mais L, de Mestier L, Baudin E, Kaltsas G, Hofland J, Garcia-Carbonero R, Tiensuu Janson E, McNamara MG, Andreassen M, Grozinsky-Glasberg S, Spada F, Leupe H, Panzuto F, Fleschen M, Klinkhammer H.   +15 more
europepmc   +2 more sources

Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm [PDF]

Endocrinology, Diabetes & Metabolism Case Reports
We present a case of recurrent thymic neuroendocrine neoplasm (NEN) in a 43-year-old male, who developed ectopic Cushing syndrome (CS), 8 years after his initial diagnosis.
Monica Majumder, Stephen Clarke, Elizabeth Bernard, Venessa H M Tsang   +3 more
doaj   +2 more sources

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. [PDF]

Cancers (Basel)
Perrone E, Calcagni ML, Leccisotti L, Moretti R, Ghai K, Eismant A, Parkar T, Greifenstein L, Baum RP.   +8 more
europepmc   +2 more sources

Combination Therapies with PRRT

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
doaj   +1 more source

Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors. [PDF]

Cancers (Basel)
Alayli A, Ngo H, Sikaria D, Ahmed A, Salloum E, Strosberg JR, Al-Toubah TE, Kis B, Haider M, El-Haddad G.   +9 more
europepmc   +2 more sources

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Journal of Pancreatology, 2023
The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu-DOTATATE. However, many aspects are still under discussion.
Wenjia Zhu, Meixi Liu, Li Huo
doaj   +1 more source